Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

HeartSciences (HSCS) Enterprise Value (2022 - 2026)

HeartSciences filings provide 5 years of Enterprise Value readings, the most recent being -$3.4 million for Q1 2026.

  • On a quarterly basis, Enterprise Value fell 30.83% to -$3.4 million in Q1 2026 year-over-year; TTM through Jan 2026 was -$3.4 million, a 30.83% decrease, with the full-year FY2025 number at -$1.1 million, up 81.07% from a year prior.
  • Enterprise Value hit -$3.4 million in Q1 2026 for HeartSciences, down from -$2.0 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$100144.0 in Q4 2023 to a low of -$7.1 million in Q1 2024.
  • Median Enterprise Value over the past 5 years was -$2.7 million (2025), compared with a mean of -$2.9 million.
  • Biggest five-year swings in Enterprise Value: soared 96.74% in 2023 and later plummeted 3946.29% in 2024.
  • HeartSciences' Enterprise Value stood at -$3.1 million in 2022, then soared by 96.74% to -$100144.0 in 2023, then plummeted by 3946.29% to -$4.1 million in 2024, then soared by 51.85% to -$2.0 million in 2025, then crashed by 74.11% to -$3.4 million in 2026.
  • The last three reported values for Enterprise Value were -$3.4 million (Q1 2026), -$2.0 million (Q4 2025), and -$2.8 million (Q3 2025) per Business Quant data.